New hope for rare liver disease: phase 3 trial of hepalatide begins
Disease control
Not yet recruiting
This study tests a new drug called hepalatide (L47) in 150 adults with chronic hepatitis D, a serious liver infection. Participants are randomly assigned to receive either hepalatide or a placebo daily for 48 weeks, followed by an optional open-label phase. The goal is to see if …
Phase: PHASE3 • Sponsor: Shanghai HEP Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 07:59 UTC